Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.16 USD | +2.27% | +3.27% | +14.08% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 44.27M | Capitalization | 113M |
---|---|---|---|---|---|
Net income 2024 * | -49M | Net income 2025 * | -22M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.56 x |
P/E ratio 2024 * |
-1.94
x | P/E ratio 2025 * |
-5.48
x | Employees | 20 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.19% |
Latest transcript on Cellectar Biosciences, Inc.
1 day | +2.27% | ||
1 week | +3.27% | ||
Current month | +2.27% | ||
1 month | -19.39% | ||
3 months | -19.59% | ||
6 months | +32.77% | ||
Current year | +14.08% |
Managers | Title | Age | Since |
---|---|---|---|
James V. Caruso
CEO | Chief Executive Officer | 65 | 15-06-14 |
Chad J. Kolean
DFI | Director of Finance/CFO | 59 | 14-05-27 |
Andrei Shustov
CTO | Chief Tech/Sci/R&D Officer | - | 23-02-14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 74 | 17-04-06 |
Douglas Swirsky
CHM | Chairman | 54 | 17-04-06 |
John Neis
BRD | Director/Board Member | 68 | 08-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 3.16 | +2.27% | 964,677 |
24-04-30 | 3.09 | -0.32% | 533,925 |
24-04-29 | 3.1 | +2.31% | 716,440 |
24-04-26 | 3.03 | +0.33% | 686,677 |
24-04-25 | 3.02 | -1.31% | 690,802 |
Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.08% | 113M | |
+33.25% | 699B | |
+25.20% | 571B | |
-3.55% | 364B | |
+18.16% | 326B | |
+4.36% | 286B | |
+14.87% | 236B | |
+5.36% | 198B | |
-9.69% | 194B | |
-3.69% | 149B |
- Stock Market
- Equities
- CLRB Stock